Levofloxacine Kabi (Levofloxacin Hemihydrate)

Levofloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes that control DNA supercoiling and replication. By blocking these targets, the drug prevents bacterial DNA synthesis and transcription, leading to rapid bacterial cell death.

The specific dose of Levofloxacine Kabi is determined by the prescribing clinician based on the type and severity of infection, patient weight, renal function, and other clinical factors. No fixed regimen is provided here; the prescriber sets the appropriate dosing schedule.

Levofloxacine Kabi falls under an unknown pregnancy category, and safety data are limited. It should be used during pregnancy or lactation only if the potential benefits outweigh the potential risks, and after a thorough risk‑benefit assessment by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Levofloxacine Kabi contains levofloxacin, the L‑isomer of ofloxacin, offering a broader spectrum and higher potency against many Gram‑negative and Gram‑positive pathogens compared with older agents such as ciprofloxacin. It also provides a more favorable dosing schedule for intravenous therapy, though safety considerations remain similar across the class.

Levofloxacine Kabi should be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. Do not use the product if it has been exposed to temperatures outside this range.

Levofloxacine Kabi is given as an intravenous infusion. The injectable solution is reconstituted according to the manufacturer's instructions and administered over the recommended infusion time, typically under the supervision of a qualified healthcare professional.

Serious adverse events include tendon rupture or inflammation, QT interval prolongation leading to potentially life‑threatening arrhythmias, Clostridioides difficile‑associated colitis, severe allergic reactions such as anaphylaxis, and peripheral neuropathy. Patients should be monitored closely for any signs of these conditions.

Levofloxacine Kabi is contraindicated in individuals with a known hypersensitivity to levofloxacin, other fluoroquinolones, or any component of the formulation. It should also be avoided in patients with a history of tendon disorders related to fluoroquinolone use, uncontrolled arrhythmias, or severe renal impairment without dose adjustment.